RECURRENT HODGKIN LYMPHOMA
Clinical trials for RECURRENT HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
Disease control Recruiting nowThis phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental combo aims to tackle tough lymphomas
Disease control Recruiting nowThis early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Vitamin c boost: could high doses help chemo fight tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy can help kill cancer cells better in people with certain blood cancers that have returned or not responded to treatment. It includes adults with relapsed or refractory lymphoma, clonal cy…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Radioactive antibody combo aims to beat back tough hodgkin lymphoma
Disease control Recruiting nowThis phase 2 trial tests a new approach for people with Hodgkin lymphoma that has not responded to treatment or has come back. It combines a radioactive antibody (yttrium-90 labeled anti-CD25) with standard BEAM chemotherapy before a stem cell transplant. The goal is to see if th…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC